Table of contents

01 - Pre-Meeting Briefing prepared by NICE

02 - Submission from the company - Boehringer Ingelheim

03 - NICE request to the company for clarification on their submission

04 - Company clarification response

05 - Exacerbation-related disutility used in the model

06 - Consultee submission - Action for Pulmonary Fibrosis

07 - Consultee submission - British Thoracic Society

08 - Consultee submission - Royal College of Nursing

09 - Consultee submission - Royal College of Pathologists

10 - Consultee submission - United Kingdom Clinical Pharmacy Association

11 - Expert statement from MAHER

12 - Expert statement from MAYERS

13 - Expert statement from BRAY

14 - Expert statement from BURNS

15 - Evidence Review Group report prepared by Southampton Health Technology Assessment Centre (SHTAC)

16 - Evidence Review Group report - erratum

17 - Company factual accuracy check of Evidence Review Group report